In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.
Antibody-drug conjugate manufacturing includes extremely dangerous ingredients, and most legacy facilities lack the features and flows for safe handling, purifying, disposing, and more.
Turn enterprise resource management (ERM) from a checklist into a true decision system, so risk informs everyday choices before quality events become supply disruptions, delays, or regulatory exposure.
